Enliven Therapeutics (ELVN) Common Equity (2019 - 2026)

Enliven Therapeutics (ELVN) has 8 years of Common Equity data on file, last reported at $453.4 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 57.26% year-over-year to $453.4 million; the trailing twelve-month figure through Mar 2026 stood at $453.4 million (up 57.26% YoY), and the FY2025 full-year result was $459.6 million, up 48.33% from the prior year.
• Common Equity eased to $453.4 million in Q1 2026, from $459.6 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $488.5 million in Q2 2025 to a low of -$76.8 million in Q4 2022.
• A 5-year average of $247.7 million and a median of $288.4 million in 2024 frame the typical range for Common Equity.
• Across the five-year window, Common Equity plunged 190.37% in 2022 and soared 675.81% in 2023, its largest moves.
• Tracing ELVN's Common Equity over 5 years: stood at -$76.8 million in 2022, then surged by 420.09% to $245.9 million in 2023, then gained by 26.0% to $309.8 million in 2024, then soared by 48.33% to $459.6 million in 2025, then retreated by 1.36% to $453.4 million in 2026.
• Business Quant data shows ELVN's Common Equity at $453.4 million in Q1 2026, $459.6 million in Q4 2025, and $476.1 million in Q3 2025.